multiple myeloma
Coverage of multiple myeloma in the Nexus archive.
- Trial Questions Continuous Maintenance in Newly Diagnosed Myeloma
A phase III trial (ENDURANCE) found that continuous lenalidomide (Revlimid) maintenance therapy did not significantly improve overall survival in patients with standard-risk, newly diagnosed multiple myeloma. The results question the effectiveness of continuous maintenance in this patient group.
- Preparing Patients for Progression in Multiple Myeloma
Cleveland Clinic hematologist Sandra Mazzoni and host John Mangels discuss effective and empathetic communication with patients facing complex, chronic multiple myeloma in their conversation titled 'Beyond Diagnosis: Multiple Myeloma'.
- Talquetamab Regimens Boost Survival in Multiple Myeloma
A phase III trial showed that Talquetamab (Talvey) combined with daratumumab (Darzalex) and optionally pomalidomide (Pomalyst) significantly improved survival outcomes for patients with relapsed or refractory multiple myeloma compared to an active regimen.
- Too sick to work, but can they prove it? New Medicaid rule worries patients
DeAnna Brandon, a North Carolina blood cancer survivor, fears new Medicaid work requirements will jeopardize her health coverage and treatment. The Trump administration's revised medical frailty exemption requires proof of significant impairment, raising concerns among health analysts about increased coverage losses.
- STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
The article highlights positive data presented at the ASCO annual meeting for Bristol in multiple myeloma and Pfizer in lung cancer. STAT's coverage focuses on key developments from the event, emphasizing advancements in cancer treatments.